Fmr LLC Acquires 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

FMR LLC lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 7,098.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 434,369 shares of the biopharmaceutical company's stock after purchasing an additional 428,335 shares during the period. FMR LLC owned 0.28% of Ocular Therapeutix worth $3,779,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its holdings in Ocular Therapeutix by 49.6% in the second quarter. Bank of New York Mellon Corp now owns 495,635 shares of the biopharmaceutical company's stock valued at $3,390,000 after acquiring an additional 164,383 shares during the last quarter. Banco Santander S.A. boosted its holdings in Ocular Therapeutix by 81.3% during the second quarter. Banco Santander S.A. now owns 377,368 shares of the biopharmaceutical company's stock worth $2,581,000 after buying an additional 169,172 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Ocular Therapeutix by 757.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,044 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 28,309 shares during the last quarter. Atlas Capital Advisors LLC bought a new position in Ocular Therapeutix during the second quarter worth about $34,000. Finally, Aptus Capital Advisors LLC bought a new position in Ocular Therapeutix during the second quarter worth about $1,798,000. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Stock Down 2.2 %

Ocular Therapeutix stock traded down $0.20 during midday trading on Friday, reaching $8.69. The stock had a trading volume of 553,897 shares, compared to its average volume of 1,786,306. The firm's fifty day simple moving average is $10.06 and its 200-day simple moving average is $8.50. Ocular Therapeutix, Inc. has a 1-year low of $3.24 and a 1-year high of $11.77. The stock has a market capitalization of $1.37 billion, a P/E ratio of -6.58 and a beta of 1.19. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OCUL. Scotiabank began coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $16.71.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the transaction, the insider now directly owns 269,059 shares in the company, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.50% of the stock is owned by insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.